These insights suggest SP140 inhibitors (e.g., GSK761 in glioma) and SP100-AS1 silencing (in CRC) as promising strategies, while SP100’s IFN-α responsiveness in breast cancer could enhance immunotherapy. This evidence concerns the gene SP140 and central nervous system cancer.